The new issue is a long term hold, and everyone is. The Wall Street Journal reported on July 24, 1996 that insiders purchased 195,000 shares, and it appears it was six memebers. My scoop on the story is
that the share price could be in the 70's by late 1998-1999. The company is well poised and the alliances and FDA approvals could push
this stock up considerably. The intial IPO day was interesting based on sheer volume, and the block trades were impressive. The major player's are obviously trading firms, but many large purchases were individual investors. The IPO day talk was that trading would quickly go to 17-18 which was pretty accurate, but shares were hard to get intially. Some luck, others paid a premium. If you follow the volume now a bunch of 3,000 share days, then a 35,000 day, and your occasional 100,000+ days. All the 100+ days must be churning, because very little upside movement. Sales figures in line with estimates,
17 drug canidates, two awaiting FDA approval. Very good buy at these prices, if you buy small amounts say less than 2-5,000 at a time, you should get a decent price. The difference between the two companies ISIS and Andrx is who they do business with, and that income is not limited to just distribution, but product and methods. Stable above $10, $15 comfort zone, anything above is profit for this year. |
